review article | Q7318358 |
scholarly article | Q13442814 |
clinical trial | Q30612 |
P2093 | author name string | Don Morris | |
Amelia Kellar | |||
Cay Egan | |||
P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer | Q24610167 | ||
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models | Q24628852 | ||
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer | Q27026346 | ||
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma | Q27851448 | ||
Cancer statistics, 2013 | Q27860762 | ||
Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais | Q28213995 | ||
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship | Q28278682 | ||
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 | ||
Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase | Q29307795 | ||
ras oncogenes in human cancer: a review | Q29547769 | ||
Lung cancer | Q29615473 | ||
Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
LKB1 modulates lung cancer differentiation and metastasis | Q30080027 | ||
Mutational activation of c-raf-1 and definition of the minimal transforming sequence | Q30406579 | ||
A mouse model for EML4-ALK-positive lung cancer | Q30485093 | ||
Towards a lung adenocarcinoma proteome map: studies with SP-C/c-raf transgenic mice | Q33243095 | ||
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer | Q33387620 | ||
Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). | Q33498277 | ||
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane | Q33666026 | ||
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer | Q33788519 | ||
Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. | Q51555780 | ||
Conditional gene expression in the respiratory epithelium of the mouse. | Q51725452 | ||
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. | Q51776233 | ||
Conditional expression of fibroblast growth factor-7 in the developing and mature lung. | Q52169169 | ||
Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung | Q52829676 | ||
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. | Q53336523 | ||
Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. | Q53420491 | ||
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. | Q53623316 | ||
Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. | Q54334588 | ||
The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. | Q54632436 | ||
Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. | Q55091443 | ||
Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma | Q59566032 | ||
Expression of SV40 T antigen under control of rabbit uteroglobin promoter in transgenic mice | Q67944833 | ||
Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice | Q69204775 | ||
In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue | Q69919083 | ||
Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse | Q70868054 | ||
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice | Q71803596 | ||
Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance | Q72427599 | ||
Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes | Q72896685 | ||
Expression of myc family oncoproteins in small-cell lung-cancer cell lines and xenografts | Q72966611 | ||
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice | Q73038129 | ||
Clonal genetic alterations in the lungs of current and former smokers | Q73443322 | ||
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts | Q73605051 | ||
Effect of navelbine on inhibition of tumor growth, cellular differentiation and estrogen receptor status on Lewis lung carcinoma | Q73676384 | ||
Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein | Q73698300 | ||
Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice | Q74181043 | ||
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models | Q74469123 | ||
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study | Q74784116 | ||
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model | Q79106481 | ||
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor | Q79856185 | ||
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel | Q82064003 | ||
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas | Q82297408 | ||
A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens | Q42255354 | ||
Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenografts | Q42451922 | ||
Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers | Q42508199 | ||
Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene | Q42661743 | ||
H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts | Q42806772 | ||
Crizotinib--latest champion in the cancer wars? | Q42846140 | ||
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy | Q43152537 | ||
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer | Q43299264 | ||
Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development | Q43589131 | ||
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study | Q44323232 | ||
Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. | Q44435203 | ||
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer | Q44652158 | ||
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets | Q44772598 | ||
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy | Q44795389 | ||
A model of pulmonary adenocarcinoma in transgenic mice expressing the simian virus 40 T antigen driven by the rat Calbindin-D9K (CaBP9K) promoter | Q45734452 | ||
Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice | Q45872028 | ||
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study | Q46068556 | ||
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors | Q46131765 | ||
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. | Q46312574 | ||
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. | Q47745236 | ||
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors | Q34112230 | ||
Transgenic mouse models for lung cancer. | Q34150005 | ||
New driver mutations in non-small-cell lung cancer | Q34161395 | ||
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture | Q34318211 | ||
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
Abnormal centrosome amplification in the absence of p53. | Q34374717 | ||
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis | Q34444361 | ||
Insertion of the v-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer | Q34577063 | ||
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 | ||
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time | Q35033300 | ||
Tumor Suppressor Genes in Lung Cancer | Q35113183 | ||
Human lung cancer and p53: the interplay between mutagenesis and selection | Q35413576 | ||
A rapid and scalable system for studying gene function in mice using conditional RNA interference | Q35627849 | ||
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer | Q35817516 | ||
Mouse bronchiolar cell carcinogenesis. Histologic characterization and expression of Clara cell antigen in lesions induced by N-nitrosobis-(2-chloroethyl) ureas | Q35830432 | ||
Life in the fast lane: mammalian disease models in the genomics era. | Q36135110 | ||
EML4-ALK fusion lung cancer: a rare acquired event | Q36485308 | ||
Definition of the human raf amino-terminal regulatory region by deletion mutagenesis | Q36766229 | ||
Etoposide in the management of non-small cell lung cancer | Q37155339 | ||
Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model | Q37412014 | ||
Progress and applications of mouse models for human lung cancer | Q37685745 | ||
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer | Q38075218 | ||
Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma | Q38303978 | ||
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells | Q39111275 | ||
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo | Q39843658 | ||
Grape seed proanthocyanidins inhibit the growth of human non-small cell lung cancer xenografts by targeting insulin-like growth factor binding protein-3, tumor cell proliferation, and angiogenic factors | Q39888381 | ||
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. | Q39893186 | ||
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? | Q39973091 | ||
mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft | Q40181537 | ||
p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment | Q40212070 | ||
Conjugated linoleic acid reduced metastasized LL2 tumors in mouse peritoneum | Q40245759 | ||
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma | Q40275475 | ||
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras | Q40424687 | ||
Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. | Q40458801 | ||
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xeno | Q40527533 | ||
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Q40647641 | ||
Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor | Q40965905 | ||
Homozygous deletions of human chromosome 3p in lung tumors. | Q41119371 | ||
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma | Q42017054 | ||
Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes | Q42053053 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung neoplasm | Q15124212 |
lung cancer | Q47912 | ||
animal disease model | Q64732998 | ||
murine model | Q122890741 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 621324 | |
P577 | publication date | 2015-01-01 | |
2015-05-03 | |||
P1433 | published in | BioMed Research International | Q17509958 |
P1476 | title | Preclinical Murine Models for Lung Cancer: Clinical Trial Applications | |
P478 | volume | 2015 |